Unique ID issued by UMIN | UMIN000004088 |
---|---|
Receipt number | R000004854 |
Scientific Title | Efficacy and safety of response-guided pegylated-interferon alpha-2a mono therapy in hemodialysis patients with chronic hepatitisC |
Date of disclosure of the study information | 2010/08/27 |
Last modified on | 2018/09/21 09:45:03 |
Efficacy and safety of response-guided pegylated-interferon alpha-2a mono therapy in hemodialysis patients with chronic hepatitisC
Efficacy and safety of response-guided pegylated-interferon alpha-2a mono therapy in hemodialysis patients with chronic hepatitisC
Efficacy and safety of response-guided pegylated-interferon alpha-2a mono therapy in hemodialysis patients with chronic hepatitisC
Efficacy and safety of response-guided pegylated-interferon alpha-2a mono therapy in hemodialysis patients with chronic hepatitisC
Japan |
Chronic hepatitis C
Hepato-biliary-pancreatic medicine |
Others
NO
Efficacy and safety of response-guided pegylated-interferon alpha-2a mono therapy in hemodialysis patients with chronic hepatitisC
Safety,Efficacy
Negative result of HCV RNA test at 24 weeks after terminating therapy
Interventional
Parallel
Non-randomized
Open -no one is blinded
Dose comparison
3
Treatment
Medicine |
PEG-IFN alfa2a weekly for 24weeks in patients with negative results of HCV RNA test at week4 of therapy (GroupA)
PEG-IFN alfa2a weekly for 48weeks in patients with negative results of HCV RNA test at week12 of therapy (GroupB)
PEG-IFN alfa2a weekly for 72weeks in patients with negative results of HCV RNA test at week36 of therapy (GroupC)
18 | years-old | <= |
70 | years-old | >= |
Male and Female
The following patients with chronic hepatitis C were eligible to enter the trial
1) The patients were hemodialysis at least 3months and had detectable HCV RNA
2)Serogroup doesn't ask it
3)Neutrophil count >=1,500/mm3.Hemoglobin concentration >10g/dL.Platelet count >=90,000/mm3
4) The presence of the liver biopsy is not asked
5) From 18 years old or over to 70years old or less
6)Patients who provided written informed consents to participate the study prior to enrollment
The following patients were excluded
1)Allegic history to interferon preparations
2)Autoimmune hepatitis,alcoholic liver injury,or chronic liver diseases with other underlying causes
3)Liver cirrhosis,decompensated liver diseases
4) Abnormal thyroid function
5)Concomitant herbal medication of Sho-saikoto
6) history of interstitial pneumonia
7) Women of childbearing potential and pregnancy, lactating woman
8)severe depression
9)Allergic to vaccine or biological preparations
10)Other conditions considered inappropriate by attending physician
50
1st name | |
Middle name | |
Last name | Satoshi Mochida |
Saitama Medical University
Division of Gastroenterology and Hepatology,internal Medicine
38,Morohongou,Moroyama-cho,Iruma-gun,Saitama,Japan
1st name | |
Middle name | |
Last name |
Saitama Medical University
Division of Gastroenterology and Hepatology,internal Medicine
38,Morohongou,Moroyama-cho,Iruma-gun,Saitama,Japan
Saitama Medical University
None
Self funding
NO
埼玉医科大学病院(埼玉県)、おおしまクリニック(埼玉県)、かみのクリニック(埼玉県)、クボジマクリニック(埼玉県)、くまがやクリニック(埼玉県)、こいづかクリニック(埼玉県)、さやま腎クリニック(埼玉県)、シャローム鋤柄医院(埼玉県)、越生メディカルクリニック(埼玉県)、岡村記念クリニック(埼玉県)、岡病院(埼玉県)、寄居本町クリニック(埼玉県)、高坂医院(埼玉県)、小川病院(埼玉県)、松本クリニック(埼玉県)、池袋病院(埼玉県)、東松山メディカルクリニック(埼玉県)、東松山宏仁クリニック(埼玉県)、東飯能駅前クリニック(埼玉県)、関越病院(埼玉県)、南町クリニック(埼玉県)、入間駅前クリニック(埼玉県)、入間台クリニック(埼玉県)、武蔵嵐山病院(埼玉県)、若葉内科クリニック(埼玉県)
2010 | Year | 08 | Month | 27 | Day |
Unpublished
Completed
2010 | Year | 07 | Month | 12 | Day |
2010 | Year | 08 | Month | 01 | Day |
2010 | Year | 08 | Month | 24 | Day |
2018 | Year | 09 | Month | 21 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004854